Compass Therapeutics, Inc. (CMPX) Stock
CMPX has an Alpha Score of 17 out of 100 (poor), computed on Nov 6, 2026 from 2 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported CMPX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $10.32M. Company insiders reported 2 open-market buys and 0 sales on SEC Form 4 in the 90 days to Nov 9, 2026.
What is CMPX's Alpha Score?
How it works →Alpha Score of 17 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own CMPX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 4.71M | $10.32M | +457% |
| Citadel Ken Griffin | 3.57M | $7.82M | +395% |
| Blackstone | 900K | $1.97M | -52% |
| Point72 Steve Cohen | 687K | $1.50M | NEW |
| Marshall Wace | 335K | $733.4K | NEW |
| D.E. Shaw David Shaw | 204K | $447.8K | +210% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Compass Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Lerner Neil | Chief Accounting Officer | BUY | 20.0K | $18K |
| Sep 24, 26 | Lerner Neil | Chief Accounting Officer | BUY | 2.5K | $3K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are CMPX's key statistics?
Key statistics as of Nov 6, 2026
CMPX price chart
Powered by TradingViewWhat does Compass Therapeutics, Inc. do?
Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to harnessing the power of the immune system to combat cancer and other serious diseases. The primary focus of Compass Therapeutics is on the development of next-generation monoclonal antibodies, with an innovative approach that combines these antibodies with other therapeutic modalities to create synergistic effects. The company operates within the biotechnology and healthcare sector, wielding a significant potential impact on the treatment of various cancers. By leveraging a proprietary scientific platform, Compass Therapeutics aims to discover and develop novel therapeutics that could transform the standard of care in oncology. Within the financial market, Compass Therapeutics represents a segment of the emerging biotech space, where cutting-edge research and clinical trials play a critical role in determining market performance and investor interest. Founded with a mission to solve complex medical challenges, Compass Therapeutics continues to advance its pipeline through rigorous research, underscoring its commitment to improving patient outcomes.